Tuberculosis, Multidrug-Resistant
Information
- Disease name
- Tuberculosis, Multidrug-Resistant
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03896685 | Active, not recruiting | Phase 3 | Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) | April 6, 2020 | November 2024 |
| NCT02715271 | Active, not recruiting | Study of TB Lesions Obtained in Therapeutical Surgery | September 2016 | July 2025 | |
| NCT05117788 | Active, not recruiting | Bioneer IRONqPCR ™ RFIA Kit Kit Clinical Evaluation | February 23, 2022 | June 1, 2024 | |
| NCT04179500 | Active, not recruiting | Phase 2 | A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers | September 16, 2021 | August 30, 2024 |
| NCT02170441 | Completed | Global Consortium for Drug-resistant Tuberculosis Diagnostics | April 2012 | June 2014 | |
| NCT02365623 | Completed | Phase 2 | An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) | February 18, 2015 | November 8, 2018 |
| NCT02413931 | Completed | Nosocomial Transmission of MDR-TB in Bucharest, Romania | May 2015 | January 2020 | |
| NCT02573350 | Completed | Phase 2 | A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 | March 26, 2009 | October 27, 2011 |
| NCT02589782 | Completed | Phase 2/Phase 3 | Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) | January 2017 | August 5, 2022 |
| NCT02597621 | Completed | Biomarkers for Therapy Response in Drug-resistant Tuberculosis | March 2013 | January 2021 | |
| NCT02754765 | Completed | Phase 3 | Evaluating Newly Approved Drugs for Multidrug-resistant TB | December 2016 | June 2023 |
| NCT03086486 | Completed | Phase 3 | Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis | November 21, 2017 | February 8, 2022 |
| NCT03259269 | Completed | Expand New Drugs for TB [endTB] | April 1, 2015 | December 30, 2019 | |
| NCT03303963 | Completed | DIAgnostics for Multidrug Resistant Tuberculosis in Africa | May 4, 2017 | November 30, 2022 | |
| NCT03338621 | Completed | Phase 2/Phase 3 | Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients | July 30, 2018 | June 10, 2022 |
| NCT00513396 | Completed | Phase 2/Phase 3 | High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis | January 2004 | December 2006 |
| NCT01071603 | Completed | Tuberculosis in China | February 2, 2010 | January 29, 2018 | |
| NCT01201941 | Completed | Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru | November 2004 | March 2009 | |
| NCT01918397 | Completed | Phase 2 | Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB | January 2015 | March 29, 2022 |
| NCT03728725 | Completed | Xpert MTB/XDR Clinical Evaluation Trial | July 11, 2019 | August 18, 2020 | |
| NCT04239326 | Completed | Clinical Evaluation of tNGS for Diagnosis of DR-TB | April 16, 2021 | June 30, 2023 | |
| NCT06441006 | Not yet recruiting | Phase 3 | Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis | November 1, 2024 | November 30, 2029 |
| NCT05007795 | Not yet recruiting | N/A | Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis | July 2023 | July 2027 |
| NCT05871489 | Recruiting | Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens | September 22, 2020 | June 30, 2027 | |
| NCT01212003 | Recruiting | Training Protocol on the Natural History of Tuberculosis | June 30, 2011 | ||
| NCT05306223 | Recruiting | Phase 4 | A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China | May 10, 2022 | August 8, 2025 |
| NCT05555303 | Recruiting | Phase 2 | Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis | March 1, 2023 | February 2026 |
| NCT03828201 | Recruiting | Phase 2 | Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB | June 7, 2022 | May 2027 |
| NCT05007821 | Recruiting | Phase 2 | Linezolid Dosing Strategies in Drug-Resistant TB | August 11, 2022 | November 14, 2025 |
| NCT05022238 | Recruiting | Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia | August 1, 2022 | September 2026 | |
| NCT04783727 | Terminated | N/A | PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis | April 1, 2021 | November 1, 2022 |
| NCT03237182 | Terminated | Phase 4 | The Individualized M(X) Drug-resistant TB Treatment Strategy Study | June 14, 2017 | December 19, 2022 |
| NCT02619994 | Unknown status | Phase 2 | Treatment Shortening of MDR-TB Using Existing and New Drugs | January 2016 | June 2021 |
| NCT03409315 | Unknown status | Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients | February 10, 2018 | December 2020 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018088